4.6 Review

Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis

期刊

EUROPEAN UROLOGY
卷 69, 期 4, 页码 693-703

出版社

ELSEVIER
DOI: 10.1016/j.eururo.2015.10.047

关键词

Exercise; Prostate cancer; Quality of life; Fatigue; Adverse effects

资金

  1. Blue Cross Blue Shield Technology Assessment Committee
  2. Ferring Pharmaceuticals
  3. National Institutes of Health
  4. Cancer Research UK
  5. National Institute for Health Research
  6. AstraZeneca
  7. Astellas
  8. Janssen
  9. Ferring
  10. Ipsen
  11. Takeda
  12. Sanofi Aventis
  13. Sandoz
  14. National Institute for Health Research and Health Technology Assessments [RP-PG-0609-10181]
  15. Amgen
  16. Sanofi
  17. Bayer
  18. Medivation
  19. National Institute for Health Research [RP-DG-1213-10010] Funding Source: researchfish
  20. National Institutes of Health Research (NIHR) [RP-DG-1213-10010] Funding Source: National Institutes of Health Research (NIHR)

向作者/读者索取更多资源

Context: Exercise could be beneficial for prostate cancer survivors. However, no systematic review across cancer stages and treatment types addressing potential benefits and harms exists to date. Objective: To assess the effects of exercise on cancer-specific quality of life and adverse events in prostate cancer trials. Evidence acquisition: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, AMED, CINAHL, PsycINFO, SPORTDiscus, and PEDro. We also searched grey literature databases, including trial registers. Searches were from database inception to March 2015. Standardised mean differences (SMDs) were calculated for meta-analysis. Evidence synthesis: We included 16 randomised controlled trials (RCTs) involving 1574 men with prostate cancer. Follow-up varied from 8 wk to 12 mo. RCTs involved men with stage I-IV cancers. A high risk of bias was frequently due to problematic intervention adherence. Seven trials involving 912 men measured cancer-specific quality of life. Pooling of the data from these seven trials revealed no significant effect on this outcome (SMD 0.13, 95% confidence interval [CI] -0.08 to 0.34, median follow-up 12 wk). Sensitivity analysis of studies that were judged to be of high quality indicated a moderate positive effect estimate (SMD 0.33, 95% CI 0.08-0.58; median follow-up 12 wk). Similar beneficial effects were seen for cancer-specific fatigue, submaximal fitness, and lower body strength. We found no evidence of benefit for disease progression, cardiovascular health, or sexual function. There were no deaths attributable to exercise interventions. Other serious adverse events (eg, myocardial infarction) were equivalent to those seen in controls. Conclusions: These results support the hypothesis that exercise interventions improve cancer-specific quality of life, cancer-specific fatigue, submaximal fitness, and lower body strength. Patient summary: This review shows that exercise/physical activity interventions can improve quality of life, fatigue, fitness, and function for men with prostate cancer. (C) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据